Quote:• Combination of 3 companies with synergies in biology and indications • 2015 Pharma Services revenue of $1.5Mexpected to grow significant o Theralink® in breast cancer to expand into other indications o LymPro Test® to add significant potential to pharma services revenue potential o Leader in cell cycle biology • CLIA laboratory operating to highest standards • Introducing proprietary diagnostic tests into market in 2017 o Ovarian cancer: OvaDx® Market potential of $2B+ (replacing CA-125) o Multiple Sclerosis: MSPrecise® Market potential of $200M+ (improving Tx intervention) o Alzheimer’s disease: LymPro Test® Market potential of $3B+ (65yr Medicare screen)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.